Tag: ‘Janssen
Biocon Biologics secures market entry for its Bmab 1200 Biosimilar in...
Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan
Biocon Biologics secures US market entry date for Bmab 1200, a...
Biocon Biologics and Janssen have finalized the settlement agreement to dismiss the pending Inter Partes Review (IPR) for US 10961307 before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademarks Office